The article provides an overview of the currently known descriptions of the mechanisms and toxic effects of two drugs: doxorubicin, a first-line drug for the treatment of cancer, and the mechanisms of action of Metformin, a drug widely used for the treatment of diabetes mellitus 2. The review made with the usage of NCBI, PubMed and OxfordAcademic presents the analysis of published data on the protective effect of Metformin in its combined use with doxorubicin in an experiment in an attempt to reduce the manifestations of doxorubicin-induced cardiotoxicity. © 2021 Izdatel'stvo Meditsina. All rights reserved
In addition to the anti-diabetic effect of metformin, a growing number of studies have shown that me...
Copyright © 2016 Bonaventure Chukwunonso Obi et al. This is an open access article distributed under...
Metformin is a drug that has been used for the treatment of diabetes for 65 years. Research shows th...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Objective: The clinical use of doxorubicin, which is a strong antineoplastic agent, is limited due t...
Background: Cardiovascular complications during drug therapy is worrisome and has been known to incr...
Doxorubicin is a strong antineoplastic agent which can affects intensely on cells during the treatme...
The molecular mechanisms underlying doxorubicin-induced cardiotoxicity are still being investigated,...
Metformin is an anti-hyperglycemic biguanide drug that is widely used as the first-line prescription...
Almost half of deaths in Poland (approximately 49%) are caused by cardiovascular system diseases. It...
Item does not contain fulltextPURPOSE OF REVIEW: In patients with type 2 diabetes mellitus, treatmen...
The cytotoxic impact of metformin has been reviewed in vivo and in vitro study until now the mechani...
Metformin has been used for a long time as an antidiabetic medication for type 2 diabetes. It is use...
Background Several studies have reported that metformin can reduce the risk of hepatocellular carcin...
Abstract: Recent studies suggest that metformin, a widely used antidiabetic agent, may reduce cancer...
In addition to the anti-diabetic effect of metformin, a growing number of studies have shown that me...
Copyright © 2016 Bonaventure Chukwunonso Obi et al. This is an open access article distributed under...
Metformin is a drug that has been used for the treatment of diabetes for 65 years. Research shows th...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Objective: The clinical use of doxorubicin, which is a strong antineoplastic agent, is limited due t...
Background: Cardiovascular complications during drug therapy is worrisome and has been known to incr...
Doxorubicin is a strong antineoplastic agent which can affects intensely on cells during the treatme...
The molecular mechanisms underlying doxorubicin-induced cardiotoxicity are still being investigated,...
Metformin is an anti-hyperglycemic biguanide drug that is widely used as the first-line prescription...
Almost half of deaths in Poland (approximately 49%) are caused by cardiovascular system diseases. It...
Item does not contain fulltextPURPOSE OF REVIEW: In patients with type 2 diabetes mellitus, treatmen...
The cytotoxic impact of metformin has been reviewed in vivo and in vitro study until now the mechani...
Metformin has been used for a long time as an antidiabetic medication for type 2 diabetes. It is use...
Background Several studies have reported that metformin can reduce the risk of hepatocellular carcin...
Abstract: Recent studies suggest that metformin, a widely used antidiabetic agent, may reduce cancer...
In addition to the anti-diabetic effect of metformin, a growing number of studies have shown that me...
Copyright © 2016 Bonaventure Chukwunonso Obi et al. This is an open access article distributed under...
Metformin is a drug that has been used for the treatment of diabetes for 65 years. Research shows th...